Genuity Capital Markets
http://www.genuitycm.com/Genuity Capital Markets is a financial services firm providing investment banking, institutional sales and trading, and equity research to its corporate clients. The firm uses a simple Buy, Hold and Sell rating system in its research analysis.
View Older Stories View More Recent Stories
-
Canaccord Genuity Maintains a 'Hold' on Research In Motion (RIMM); Q1/F2012 preview: Checks Indicate Broad Share Losses
-
Canaccord Genuity Adjusts Price Target and Estimates on FuelCell Energy (FCEL); Maintains 'Buy' Rating
-
Canaccord Genuity Starts SciQuest (SQI) At Buy; At The Foothills Of A Large Opportunity
-
Canaccord Genuity Maintains a 'Buy' on Voyager Oil & Gas (VOG); Compelling Bakken Valuation
-
Canaccord Genuity Reiterates a 'Buy' on Raptor Pharmaceuticals (RPTP); Cystinosis and RP-103
-
Canaccord Genuity Reiterates a 'Buy' on Sierra Wireless (SWIR); Healthy End Market Trends; Anticipate Strong H2/11
-
Canaccord Genuity Maintains a 'Hold' on Texas Instruments (TXN); Reduced Guidance a Company-Specific Event
-
Canaccord Genuity Maintains a 'Buy' on Carrizo Oil & Gas (CRZO); Raising PT Higher Capital Spending and Greater Allocation Toward Eagle Ford
-
Notable 52-Week Highs and Lows of the Day 06/08: (VRUS) (COG) (NLY) High; (TLB) (CSCO) (RIMM) Low
-
Canaccord Genuity Maintains a 'Hold' on Edwards Lifesciences (EW); TVT Takeaways and Other TAVI Musings; Stay on Sidelines
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Tempered Nexavar Outlook in Breast Cancer
-
Canaccord Genuity Maintains a 'Buy' on EnerNOC (ENOC); Analyst Day Initial Thoughts
-
Canaccord Genuity Reiterates a 'Buy/Best Idea' on NCI Building Systems (NCS); Recent Sell-off Unwarranted
-
UPDATE - Canaccord Genuity Upgrades Cabot Oil & Gas (COG) to Buy; Most Productive Gas Asset in North America
-
Canaccord Genuity Upgrades Cabot Oil & Gas (COG) to Buy
-
Notable ETF Movers of the Day 06/07: (XRT) (SMH) (XLE) Higher; (VXX) (UNG) (UUP) Lower
-
Canaccord Genuity Maintains a 'Hold' on Exelixis (EXEL); Improved Visibility on Cabo CRPC Registration Path
-
Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Phase 2A CK357 Claudication Data: Supports Mechanism but Shows Noisy CNS Safety Profile
-
Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Tivo Still Positioned Well in the Face of Decent Axitinib Data
-
Canaccord Genuity Maintains a 'Hold' on U.S. Ecology (ECOL); Hudson River Dredging Resumes, Potential Positive
-
Canaccord Genuity Reiterates a 'Buy' on Pegasystems (PEGA); PegaWORLD: BPM Leadership on Display
-
Canaccord Genuity Maintains a 'Buy' on Atmel (ATML); Growth Opportunities for Touch and General MCU
-
Canaccord Genuity Reiterates a 'Buy' on Apple (AAPL); Raising PT & Estimates After Positive WWDC
-
Canaccord Genuity Maintains a 'Hold' on Transocean (RIG); Mid-Quarter Update
-
Canaccord Genuity Reiterates a 'Buy' on Halliburton (HAL); Downside on Lawsuit Seems Excessive
-
Unusual 11 Mid-Day Movers 06/06: (ADES) (ZN) (COOL) Higher; (EXEL) (SNSS) (BAP) Lower
-
Canaccord Genuity Maintains a 'Hold' on Exelixis (EXEL); New Cabo Data Could Complicate FDA Strategy; Remain Cautious
-
Canaccord Genuity Maintains a 'Buy' on EnerNOC (ENOC); FERC Finding is More Favorable, but Not Final
-
Notable 52-Week Highs and Lows of the Day 06/03: (SOLR) (FRX) (NFLX) High; (CSCO) (OREX) (RIMM) Low
-
Canaccord Genuity Reiterates a 'Buy' on Insulet (PODD); Acquires Neighborhood Diabetes; Sets the Table for Growth
-
Canaccord Genuity Reaffirms a 'Buy' on Heartware Intl (HTWR); Management Meeting Takeaways Reaffirm Thesis
-
Canaccord Genuity Reiterates a 'Buy' on DexCom (DXCM); Animas Receives CE Mark Approval for VIBE (Combo CGM/pump); Milestone Due
-
Canaccord Genuity Maintains a 'Hold' on Cyberonics (CYBX); Weak OUS Sales Impact Qtr and Guidance; US Strength Continues
-
Canaccord Genuity Maintains a 'Hold' on Terex (TREX); Sluggish Trends Present Risk to Q2 Estimates
-
Canaccord Genuity Maintains a 'Buy' on FuelCell Energy (FCEL); Q2 Preview
-
Canaccord Genuity Maintains a 'Hold' on Universal Display (PANL); Increased litigation Risk and Lack of Catalysts Likely to Weigh on Shares
-
Canaccord Genuity Maintains a 'Hold' on United Natural Foods (UNFI); Acceleration Ends and Growth Normalizing, but Outlook for Growth Remains
-
Canaccord Genuity Reiterates a 'Buy' on ANSYS (ANSS); On the Road with Management
-
Canaccord Genuity Reiterates a 'Buy' on New Gold (NGD); Blackwater Acquisition and Revised Peak Gold Price Improve Valuation
-
Anthera Pharmaceuticals (ANTH) To Offer Common Shares
-
Notable 52-Week Highs and Lows of the Day 06/02: (AFFX) (BRCD) (NLY) High; (PSUN) (JNY) (CWTR) Low
-
It's Time for Dell (DELL) to Buy Brocade (BRCD) - Analyst
-
Canaccord Genuity Reiterates a 'Buy' on Quidel Corp. (QDEL); Clinical Trials Advance
-
Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Takeaways From Meetings on the Road with Management
-
Canaccord Genuity Reiterates a 'Buy' on Hologic (HOLX); Expanding Presence in China
-
Canaccord Genuity Reiterates a 'Buy' on Qualcomm (QCOM); Upbeat Uplinq Conference
-
Notable Analyst Rating Changes 06/01: (BLK) (ESV) (CNP) Upgraded; (NOK) (SQNS) (HNZ) Downgraded
-
Morning Movers 06/01: (TLVT) (OREX) Higher; (SPU) (AMSC) (MPET) (JOSB) Lower
-
Canaccord Genuity Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Full Lomitapide Phase 3 Data Supports Best-in-Class Status
-
Canaccord Genuity Reiterates a 'Buy' on AVEO Pharmaceuticals (AVEO); License Agreement Supports Platform Potential
